Gastric Proton Pumpopathy Associated with Protein Sorting Machinery: A Narrative Review

胃质子泵病与蛋白质分选机制相关:一篇叙述性综述

阅读:2

Abstract

BACKGROUND: Gastric acid secretion by parietal cells depends on the trafficking and exocytosis of H⁺/K⁺-ATPase-rich tubulovesicles (TVs) to the apical membrane in response to histamine stimulation via cyclic AMP elevation. However, the role of parietal cell's protein sorting machinery [eg, coat protein (COP) II/COP I vesicle proteins, soluble NSF attachment protein receptors (SNAREs), Rab GTPases, clathrin-adaptor proteins, etc.] in the dysregulation of gastric acid homeostasis remains poorly understood. This review synthesizes available evidence on the role of protein sorting machinery in gastric proton pumpopathy, leading to dysregulation of gastric acid secretion. METHODS: A thorough search was conducted on PubMed, with Wiley and African Journal Online as supplementary sources, and 15 original research articles published between January 1988 and July 2025 in English were included. RESULTS: Misfolding of α- and β-subunits within the endoplasmic reticulum (ER) results in retention and degradation of the pump, leading to impaired acid secretion. Defective coat protein (COP) II/I vesicular transport disrupts Golgi processing and slows the delivery of proton pumps to tubulovesicles, while impaired Rab GTPase activity interferes with vesicle targeting toward the apical canalicular membrane. Also, dysregulation of SNARE complexes and adaptor proteins prevents effective vesicle docking and fusion, further compromising membrane insertion. In addition, abnormalities in endosomal recycling pathways hinder the retrieval and reinsertion of proton pumps, destabilizing long-term acid secretion. CONCLUSION: Defects in sorting machinery lead to gastric proton pumpopathy, causing impaired acid secretion. Thus, protein sorting regulators represent promising therapeutic targets to restore proper pump localization, which is a paradigm shift toward disease-modifying therapies that act upstream of the pump, potentially offering solutions for proton pump inhibitor (PPI)-resistant cases and congenital gastric acid disorders.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。